NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

GHRS

GH Research PLC

Jul 03 • 03:39PM ET

14.91

Dollar change -0.11
Percentage change -0.77	%

Healthcare • Biotechnology • Ireland • NASD

Peers: NBIX EXEL CORT SAGE ALT AGIO URGN VKTX MNKD PRTA

| Held by: EIRL PSIL GWX BBC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.79	Insider Own	36.29%	Shs Outstand	62.03M	Perf Week	20.28%
Market Cap	925.15M	Forward P/E	-	EPS next Y	-1.52	Insider Trans	0.00%	Shs Float	39.52M	Perf Month	23.47%
Enterprise Value	634.46M	PEG	-	EPS next Q	-0.21	Inst Own	66.32%	Short Float	6.97%	Perf Quarter	43.41%
Income	-42.11M	P/S	-	EPS this Y	-25.50%	Inst Trans	133.53%	Short Ratio	14.87	Perf Half Y	98.87%
Sales	0.00M	P/B	2.98	EPS next Y	-62.02%	ROA	-15.65%	Short Interest	2.76M	Perf YTD	113.07%
Book/sh	5.00	P/C	3.18	EPS next 5Y	-26.55%	ROE	-16.20%	52W High	20.50 -27.24%	Perf Year	26.94%
Cash/sh	4.70	P/FCF	-	EPS past 3/5Y	-61.76% -179.37%	ROIC	-13.56%	52W Low	6.00 148.58%	Perf 3Y	48.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.05% 8.62%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-26.82%	Oper. Margin	-	ATR (14)	1.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	29.71	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	66.16	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	29.71	EPS Q/Q	-26.48%	SMA20	16.66%	Beta	0.95	Target Price	33.14
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	28.19%	Rel Volume	0.56	Prev Close	15.03
Employees	50	LT Debt/Eq	0.00	Earnings	May 08 BMO	SMA200	49.94%	Avg Volume	185.30K	Price	14.91
IPO	Jun 25, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	47.95% -	Trades		Volume	99,435	Change	-0.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-04-25	Resumed	Cantor Fitzgerald	Overweight	$25
Mar-13-25	Initiated	Guggenheim	Buy	$32
Mar-07-25	Initiated	RBC Capital Mkts	Outperform	$31
Feb-13-25	Initiated	Cantor Fitzgerald	Overweight	$14
Aug-16-22	Initiated	H.C. Wainwright	Buy	$45
Jun-16-22	Initiated	ROTH Capital	Buy	$66

Jun-23-25 09:51AM	Compasss Psychedelic Drug to Treat Depression Meets Goal in Trial (Bloomberg) -5.12%
Jun-20-25 01:00PM	GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule (GlobeNewswire)
Jun-19-25 10:10AM	Trump Trade: President said to weigh possible U.S. strike against Iran (TipRanks)
09:26AM	Psychedelic advocates hopeful Trump administration will support space, STAT says (TipRanks)
May-15-25 07:00AM	GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting (GlobeNewswire) +7.21%
11:11AM	Loading…
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
May-08-25 07:00AM	GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +5.16%
May-05-25 12:00PM	What Makes GH Research (GHRS) a New Buy Stock (Zacks)
Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks)
Mar-13-25 05:30PM	Guggenheim starts GH Research at Buy, sees long-term upside potential (TipRanks)
Mar-03-25 11:06AM	Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025 (Insider Monkey) -9.08%
Mar-01-25 11:00AM	GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
07:00AM	Loading…
Feb-27-25 07:00AM	GH Research Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-24-25 01:49PM	GH Research PLC (GHRS): Among the Best Performing Small Cap Stocks So Far In 2025 (Insider Monkey)
Feb-04-25 08:52PM	GH Research Announces Pricing of $150 Million Public Offering (GlobeNewswire) -9.31% -8.06%
Feb-03-25 08:22PM	Why GH Research PLC (GHRS) Is Skyrocketing So Far In 2025 (Insider Monkey) +69.72%
04:03PM	GH Research Announces Proposed Public Offering (GlobeNewswire)
07:07AM	Shares of psychedelics biotech nearly double on depression data (BioPharma Dive)
07:00AM	GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction (GlobeNewswire)
Jan-31-25 04:01PM	GH Research to Provide Update on Phase 2b Trial with GH001 in TRD (GlobeNewswire) +9.39%
Jan-10-25 07:00AM	GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents (GlobeNewswire)
Nov-20-24 09:55AM	Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect? (Zacks) +13.94%
Nov-18-24 07:19AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-14-24 07:00AM	GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Sep-09-24 12:00PM	GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade (Zacks)
09:35AM	After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS) (Zacks)
Sep-08-24 09:14PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
07:05AM	Loading…
Sep-03-24 07:05AM	GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.57%
07:00AM	GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer (GlobeNewswire)
Jul-06-24 07:21AM	3 Psychedelic Stocks to Ride to the Moon and Beyond (InvestorPlace)
Jul-03-24 09:48AM	Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns (InvestorPlace)
May-13-24 08:50AM	Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why (Zacks)
May-10-24 09:55AM	Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know (Zacks) +6.84%
May-03-24 01:53PM	GHRS Stock Earnings: GH Research Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-24 09:55AM	How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28% (Zacks)
Feb-29-24 07:00AM	GH Research Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire) +7.90%
Jan-18-24 04:30PM	GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression (GlobeNewswire)
Jan-16-24 09:55AM	Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-29-23 08:47AM	11 Best Psychedelic Stocks to Buy in 2024 (Insider Monkey)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey) -7.32%
Dec-19-23 11:07AM	15 Best Falling Stocks To Buy Now (Insider Monkey) +9.13%
Nov-09-23 04:45PM	GH Research Reports Third Quarter Financial Results and Provides Business Updates (GlobeNewswire)
Sep-29-23 04:45PM	GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression (GlobeNewswire)
Aug-23-23 07:00AM	GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-17-23 11:53AM	Here's Why We're Not Too Worried About GH Research's (NASDAQ:GHRS) Cash Burn Situation (Simply Wall St.)
Jul-06-23 09:40AM	Its Really a Brain Chemistry Issue: Elon Musk Embraces Ketamine in the Battle Against Depression Here Are 2 Psychedelic Stocks That Analysts Like (TipRanks)
Jun-29-23 08:00AM	The 3 Best Psychedelic Stocks to Buy Now (InvestorPlace)
May-11-23 07:30AM	GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-23-23 01:56PM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks) +14.78%
Mar-12-23 12:22PM	10 Best Psychedelic Stocks to Buy According to Hedge Funds (Insider Monkey)
Mar-02-23 07:00AM	GH Research Reports Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-07-23 10:15AM	GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jan-09-23 07:30AM	GH Research Provides Business Updates and Highlights Key Upcoming Milestones (GlobeNewswire) -13.00%
Nov-21-22 12:22PM	7 Short-Squeeze Stocks for Bold Contrarians to Consider (InvestorPlace) -6.67%
Nov-10-22 07:05AM	GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +7.03%
Sep-14-22 09:55AM	Wall Street Analysts See a 262% Upside in GH Research PLC (GHRS): Can the Stock Really Move This High? (Zacks) +9.26%
Aug-30-22 03:02PM	7 Psychedelics Stocks to Buy for a Big Drug Boom (InvestorPlace) -6.01%
Aug-29-22 09:55AM	Wall Street Analysts Predict a 206% Upside in GH Research PLC (GHRS): Here's What You Should Know (Zacks) +7.95%
Aug-23-22 07:00AM	GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +5.33%
May-18-22 07:00AM	GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) -9.98%
Mar-28-22 07:04AM	GH Research Reports Full Year 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-24-22 11:48AM	We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn Rate (Simply Wall St.)
Dec-06-21 07:10AM	GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire) +21.86%
07:00AM	GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression (GlobeNewswire)
Oct-27-21 04:50AM	10 Pharma Stocks to Buy According to Mark Lamperts Biotechnology Value Fund (Insider Monkey) +10.61%
Sep-25-21 10:07AM	We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth (Simply Wall St.)
Sep-23-21 05:25PM	GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-02-21 04:20PM	Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies (Benzinga) -5.64%
Jun-25-21 01:23PM	7 Companies Go Public Today. What Investors Need to Know. (Barrons.com)

GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schonharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GHRS

GH Research PLC

Upgrade your FINVIZ experience